herman.w@todosmedical.com

Chuck, all excellent questions, but I would need to sign an NDA before diving deeper into the answers, happy to do so. Please reach out herman.w@todosmedical.com

Chuck, i want to add, the quote of 'could be as high is 90%' was clearly aspirational based on targets that have been developed with pharma in mind, to your second question.

Hi Brian, There is a point in time when the immune system does indeed react to the malignant change and shift from tumor suppressive to tumor tolerant and there is an interaction that the tumor 'turns off' the host reaction to fight it, we have shown data indicating we can still pick up these changes.

There are competitors looking at circulating DNA from tumor cells, but this usually happens later in the disease process and not early

Harry, Our KOLs and Pharma contacts are all eager as well

Sorry David, i have been traveling, please see my answer

Hi Chuck, Just logged in for the first time since this went live, and seeing some great feedback. We are putting together our data package, but need to take care of a few things before we can publicise it. The KOLs we have canvased and the Pharma companies have all told us that any diagnostic that pushes the diagnosis earlier will be highly sought after

Sorry for the delay Chuck, no trying to be evasive, I was traveling for the last 2 weeks, There was a conference in Vegas and followed by investor meetings in NYC. To directly answer your question we are working on getting the data out publicly in the right time and forum. There is a process here we are trying to be cognisant of and stay within the lines.

We are planning on working with pharma companies who are working on developing drugs in the space, all drug trials have failed because they are started too late in the disease process, our test will allow for earlier diagnoses and entry into the clinical trials when disease modification can actually succeed